PDUFA Date

Viatris awaits Dec. 27 FDA verdict on non-opioid pain drug meloxicam-107A-02

Two positive Phase 3 trials backed the NDA for fast-acting meloxicam; the FDA's review now turns on whether that data supports a non-opioid first-line option for acute pain.

By AppliedXLJuly 13, 2026Trial NCT06215820

Executive Summary

The FDA has accepted Viatris's application for a fast-acting meloxicam formulation for acute post-surgical pain and set a firm decision date at the end of 2026.
The filing rests on a completed Phase 3 program that already reported a positive primary endpoint against placebo, with an opioid comparator arm included to confirm the pain model worked.
Viatris is positioning the drug as a non-opioid alternative for a pain population still commonly treated with opioids, and the FDA review will decide whether that positioning holds without additional study.
No competing program shares this molecule's exact profile as a fast-acting oral NSAID with a completed Phase 3 program in this surgical-pain setting, though multiple non-opioid alternatives are already marketed or in later-stage testing for the same indication.

The filing

The FDA accepted Viatris's New Drug Application for MR-107A-02, described as fast-acting meloxicam, a non-opioid treatment for moderate-to-severe acute pain, and assigned a PDUFA goal date of December 27, 2026. The application uses the 505(b)(2) pathway, which allows a sponsor to rely in part on existing safety data for a previously characterized drug rather than generating a full new safety package from scratch. Viatris Chief R&D Officer Philippe Martin said the filing is intended "to bring a potential non-opioid first-line treatment option to patients with moderate-to-severe acute pain". The submission covers two pivotal trials, one in herniorrhaphy patients (NCT06215859) and one in bunionectomy patients (NCT06215820). U.S

Probability of Success

Endpoint Met65%

Completes95%

Clinical Significance9%

Regulatory87%

The trial behind the filing

The bunionectomy study, NCT06215820, enrolled 410 adult patients and completed in 2024, randomizing them to MR-107A-02, placebo, or tramadol 50mg every six hours as an active comparator to confirm the pain model was sensitive enough to detect a drug effect. The registered primary endpoint was the Summed Pain Intensity Difference (SPID), a composite measure of pain relief over time, measured against placebo over the first 48 hours after surgery. Viatris reported in May 2025 that the trial met its primary endpoint, with an LS mean difference in SPID0-48h of 82.7 versus placebo (95% CI 62.0-103.4, p<0.001), and that 56.9% of patients on MR-107A-02 required no opioid rescue medication versus 33.1% on placebo (p<0.001). The company described the safety profile as comparable to placebo. NCT06215820+1

Registry housekeeping

The trial's operational history shows enrollment moving from 405 to 408 to 410 patients and its status shifting from Recruiting to Active-not-recruiting in September 2024 as enrollment closed at target, then to Completed the following month, alongside a one-month pull-forward in primary completion date to August 24, 2024. That enrollment path reflects the trial reaching its target of 410, not a change in trial size, and the registry shows no primary-endpoint amendment after completion. The operational signal here is a clean, on-schedule finish; the open item for the program is regulatory review, not trial execution. NCT06215820

The competitive frame

Postoperative pain is a crowded therapeutic area on modality but not on this specific molecule: comparators in active development or already marketed for the same surgical-pain setting include long-acting local anesthetics such as bupivacaine liposome and ZYNRELEF, opioids and opioid-adjacent agents such as dezocine and sufentanil, and next-generation non-opioid analgesics such as suzetrigine, none of which share meloxicam's COX-2-inhibiting mechanism in this indication. Because meloxicam itself is an approved, long-characterized NSAID, the regulatory question for this filing centers on whether the fast-acting formulation and its specific acute-pain claim, not the underlying mechanism, hold up under FDA review. No designation such as Breakthrough Therapy, Priority Review, or Fast Track attaches to this application on record. U.S

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.